Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovarian Cancer Efficacy Data ...
Source: marketscreener.com